Novo walks away from its Hims & Hers partnership after eight weeks
Novo said the telehealth company kept selling compounded semaglutide under the label of personalisation. The deal to offer branded Wegovy through the platform ended.
Who feels it
-
Sellers
Rethink
Shows makers will cut ties with partners that keep selling copies.
-
Patients
Adjust
If you used the platform for Wegovy, check how your supply now reaches you.
-
Prescribers
Worth knowing
A reminder to ask patients exactly what product their online service ships.
-
Pharmacies
Worth knowing
Little direct effect on store pharmacies.
-
Payers
Passes by
No direct effect.
What happened
In late April 2025, Novo Nordisk and Hims & Hers announced a partnership to offer branded Wegovy through the telehealth platform. Eight weeks later, Novo ended it.
Novo’s reason
Novo said Hims & Hers continued to sell compounded semaglutide in large volumes, describing it as “personalised.” Novo called this a practice that put patients at risk and broke the spirit of the deal.
The other side
Hims & Hers said it would keep offering patients options and criticised Novo’s approach.
Why it matters
After the shortage ended, the line between legal individual compounding and mass production of copies became the central fight. This was the most public test of where makers draw that line.
Source Novo Nordisk statement and Hims & Hers response, 23 June 2025
Spotted an error? Tell us through the contact form; we follow the corrections policy.
